Your browser doesn't support javascript.
loading
A tumor microenvironment-associated circRNA predictor for tumor relapse and chemotherapy vulnerability in nasopharyngeal carcinoma.
Liang, Ye-Lin; Zhao, Yu-Heng; Ding, Cong; Huang, Sai-Wei; Li, Qian; Zhu, Chong-Mei; He, Qing-Mei; Tang, Ling-Long; Mao, Yan-Ping; Chen, Lei; Li, Wen-Fei; Zhou, Guan-Qun; Liu, Na; Jiang, Wei; Ma, Jun; Li, Ying-Qin.
Affiliation
  • Liang YL; Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Center for Precision M
  • Zhao YH; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Ding C; Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Center for Precision M
  • Huang SW; Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Li Q; Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Center for Precision M
  • Zhu CM; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • He QM; Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Center for Precision M
  • Tang LL; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Mao YP; Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Center for Precision M
  • Chen L; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Li WF; Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Center for Precision M
  • Zhou GQ; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Liu N; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Jiang W; Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Center for Precision M
  • Ma J; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
  • Li YQ; Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Center for Precision M
iScience ; 26(12): 108467, 2023 Dec 15.
Article in En | MEDLINE | ID: mdl-38089590
ABSTRACT
Accurate risk stratification for patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is crucial for prognosis and treatment decisions. Here, we develop a tumor microenvironment-associated circular RNA (circRNA) signature that can stratify LA-NPC patients with different risks of relapse and vulnerability to induction chemotherapy (IC). Relapsed-related circRNAs are identified by comparing expression profiles between patients with and without relapse, followed by quantitative validation in the training cohort (n = 170). A nine-circRNA signature is constructed to classify patients into high-risk and low-risk groups. Low-risk patients have significantly favorable clinical survivals, which is validated in the internal (n = 170) and external (n = 150) cohorts. They are characterized by an immune-active microenvironment and can derive benefits from IC. Meanwhile, high-risk patients characterized with pro-relapse and DNA repair-associated features, are vulnerable to chemoresistance. Overall, the circRNA-based classifier serves as a reliable prognostic tool and might guide chemotherapy decisions for patients with LA-NPC.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: IScience Year: 2023 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: IScience Year: 2023 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA